Enhancing oxaliplatin-based regimens in colorectal cancer by inhibiting the epidermal growth factor receptor pathway

George P. Kim, Axel Grothey

Research output: Contribution to journalArticle

Abstract

In the past several years, significant advances in the treatment of colorectal cancer (CRC) have been made. With the introduction of irinotecan and oxaliplatin combined with infusional 5-fluororuracil, survival times for patients with metastatic CRC have nearly doubled. With the incorporation of biologic agents that target the vascular endothelial growth factor and epidermal growth factor (EGF) pathways, additional improvements in response, progression-free survival, and overall survival have been seen in patients with advanced, metastatic disease. This article reviews the impact of EGF receptor inhibitors on improving survival in CRC when combined with oxaliplatin- containing regimens.

Original languageEnglish (US)
Pages (from-to)S89-S97
JournalClinical colorectal cancer
Volume5
Issue numberSUPPL. 2
DOIs
StatePublished - Oct 2005

Keywords

  • 5-fluorouracil
  • Bevacizumab
  • Capecitabine
  • Cetuximab
  • Chemotherapy
  • Irinotecan

ASJC Scopus subject areas

  • Oncology
  • Gastroenterology

Fingerprint Dive into the research topics of 'Enhancing oxaliplatin-based regimens in colorectal cancer by inhibiting the epidermal growth factor receptor pathway'. Together they form a unique fingerprint.

Cite this